Jim Cramer is Optimistic About Novartis’ (NVS) Cancer Drug

Core Viewpoint - Novartis AG (NYSE:NVS) has shown significant stock performance, with a 44% increase over the past year and a 7.6% rise year-to-date, attracting attention from analysts and investors [1]. Group 1: Analyst Ratings and Price Targets - Morgan Stanley upgraded Novartis AG to Overweight, raising the price target to CHF110 from CHF108, citing that the stock had been excessively punished following third-quarter earnings due to issues with legacy products [1]. - TD Cowen maintained a Hold rating on Novartis AG with a price target of $140, suggesting that some growth projections may be overly optimistic [1]. Group 2: Product Insights and Market Sentiment - Jim Cramer highlighted Novartis AG's weight loss pill as a key early mover in the market, although he noted that medical professionals may be reluctant to recommend it to patients [1]. - Cramer expressed optimism regarding Novartis AG's cancer drug Pluvicto, indicating strong potential for the company in the oncology sector [1].